Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 4:10:1115786.
doi: 10.3389/fcell.2022.1115786. eCollection 2022.

Mesenchymal stromal/stem cell-derived exosomes and genitourinary cancers: A mini review

Aria Salehpour  1 , Saule Balmagambetova  2 , Nadiar Mussin  3 , Asset Kaliyev  3 , Farhad Rahmanifar  4
Affiliations
Review

Mesenchymal stromal/stem cell-derived exosomes and genitourinary cancers: A mini review

Aria Salehpour et al. Front Cell Dev Biol. .

Abstract

Mesenchymal stromal/stem cell- (MSC-) derived exosomes are gaining popularity for their involvement in tissue repair and repressing various tumors through extensive patterns. Nevertheless, the impact of extracellular vesicles produced by stem cells on tumor formation and progression is controversial and seems to depend on several factors. The utilization of MSCs' various capabilities in urogenital neoplasms is widely regarded as a potential future therapeutic as well. These genitourinary neoplasms include prostatic neoplasms, ovarian neoplasms, cervical neoplasms, endometrial neoplasms, bladder neoplasms, and renal cell neoplasms. The present study has concentrated on the most recent information on genitourinary neoplasms employing MSCs derived exosomes' many capabilities, such as delivering effective RNAs, extensive tissue compatibility, and specificity with tumor identification without inherent limitations of cell therapy.

Keywords: Exosomes; Genitourinary neoplasms; MSCs; Mesenchymal Stromal/Stem Cell; Reproductive cancers; Reproductive neoplasms; Urogenital neoplasms; miRNAs.

PubMed Disclaimer

Conflict of interest statement

Author AS is employed by PerciaVista R&D Co.Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Exosomal miRNAs and their therapeutic effects against genitourinary neoplasms. Summary of all available exosomal miRNAs and their effect on genitourinary neoplasms.
See this image and copyright information in PMC

References

    1. Abas B. I., Demirbolat G. M., Cevik O. (2022). Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel. PLoS One 17, e0274607. 10.1371/journal.pone.0274607 - DOI - PMC - PubMed
    1. Alcayaga-Miranda F., Gonzalez P. L., Lopez-Verrilli A., Varas-Godoy M., Aguila-Diaz C., Contreras L., et al. (2016). Prostate tumor-induced angiogenesis is blocked by exosomes derived from menstrual stem cells through the inhibition of reactive oxygen species. Oncotarget 7, 44462–44477. 10.18632/oncotarget.9852 - DOI - PMC - PubMed
    1. Bazoobandi S., Tanideh N., Rahmanifar F., Zare S., Koohi-Hosseinabadi O., Razeghian-Jahromi I., et al. (2020). Preventive effects of intrauterine injection of bone marrow-derived mesenchymal stromal cell-conditioned media on uterine fibrosis immediately after endometrial curettage in rabbit. Stem Cells Int. 2020, 8849537. 10.1155/2020/8849537 - DOI - PMC - PubMed
    1. Bozorgmehr M., Gurung S., Darzi S., Nikoo S., Kazemnejad S., Zarnani A. H., et al. (2020). Endometrial and menstrual blood mesenchymal stem/stromal cells: Biological properties and clinical application. Front. Cell Dev. Biol. 8, 497. 10.3389/fcell.2020.00497 - DOI - PMC - PubMed
    1. Brossa A., Fonsato V., Grange C., Tritta S., Tapparo M., Calvetti R., et al. (2020). Extracellular vesicles from human liver stem cells inhibit renal cancer stem cell-derived tumor growth in vitro and in vivo . Int. J. Cancer 147, 1694–1706. 10.1002/ijc.32925 - DOI - PMC - PubMed

LinkOut - more resources